COMMUNIQUÉS West-GlobeNewswire

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I [...]
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare [...]
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
01/08/2025
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025
01/08/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025
01/08/2025
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly- [...]
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01/08/2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
01/08/2025
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a [...]
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
01/08/2025
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non ‑ dilutive grant funding from [...]
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
01/08/2025
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, Susvimo maintained [...]

Pages